NCT02235688 - Study to Investigate the Safety and Activity of Aldoxorubicin Plus Gemcitabine in Subjects With Metastatic Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 31, 2014

Primary Completion Date

January 31, 2017

Study Completion Date

January 31, 2017

Conditions

Metastatic Solid Tumors

Interventions

DRUG

aldoxorubicin

administered at 170 mg/m2 by intravenous infusion (IVI) on Day 1 every 21 days plus 900 mg/m2 gemcitabine on Days 1 and 8 every 21 days.

DRUG

aldoxorubicin

administered at 250 mg/m2 by intravenous infusion (IVI) on Day 1 every 21 days plus 900 mg/m2 gemcitabine on Days 1 and 8 every 21 days.

DRUG

aldoxorubicin

administered at 350 mg/m2 by intravenous infusion (IVI) on Day 1 every 21 days plus 900 mg/m2 gemcitabine on Days 1 and 8 every 21 days.

DRUG

gemcitabine

Trial Locations (2)

Virginia G. Piper Cancer Center, Scottsdale

Sarcoma Oncology Center, Santa Monica